| Diabetic Macular Edema |
ChiCTR-TRC-12002417: A randomized controlled trial to compare the efficacy and safety of 1) macular laser vs. 2) repeated intravitreal bevacizumab vs. 3) combined repeated intravitreal bevacizumab with macular laser for diabetic macular edema |
|
|
| Suspended | 1 | 680 | | Group 1 (Control) :Macular laser photocoagulation performed every 4 months unless the deferral criteria are met. Group 2: Intravitreal bevacizumab injections (1.25mg each) given at 0, 1, 2 months and repeated en bloc every 4 months unless the deferral criteria are met. Group 3: Intravitreal bevacizumab injections (1.25mg each) given at 0, 1, 2 months, followed by macular laser photocoagulation at month 3; and repeated en bloc every 4 months unless the deferral criteria are met.. | Nil; None, Research Grant Council - General Research Fund 2009-2010 | diabetic macular edema | | | | |
| Completed | 1 | 30 | | Bevacizumab | Hospital Oftalmologico de Sorocaba; Level of the institution：, Hospital Oftalmologico de Sorocaba | Diabetic macular edema | | | | |
ChiCTR-TRC-05000666: A Randomized Controlled Trial to Compare the Safety and Efficacy of Grid Laser Versus Posterior Subtenon Triamcinolone Versus Combined Subtenon Triamcinolone and Grid Laser in the Treatment of Clinically Significant Diabetic Macular Edema |
|
|
| Completed | 1 | 90 | | Grid laser photocoagulation versus 1. Posterior subtenon triamcinolone 40mg injection 2. Combined 40mg subtenon TA injection and grid laser, 12 months | Nil; Level of the institution：, N/A | Eye Diseases | | | | |
ChiCTR-IIR-15007619: clinical research of Conbercept in the therapy of cataract combined with diabetic macular edema |
|
|
| Recruiting | 1 | 40 | | Phacoemulsification for cataract + intravitreal Conbercept injection ;Phacoemulsification for cataract | the 4th affiliated hospital of CMU; the 4th affiliated hospital of CMU, Conbercepts are provided by the Kanghong biological technology co. | cataract with diabetic macular edema | | | | |
NCT04005430: A Phase I Study of Episcleral Dexamethasone for Treatment of Macular Edema |
|
|
| Active, not recruiting | 1 | 1 | US | Episcleral Dexamethasone, Sustained Release Transscleral Dexamethasone | Targeted Therapy Technologies, LLC | Refractory Diabetic Macular Edema | 09/24 | 09/24 | | |
NCT05489718: A Dose Escalation Study of IBI324 in Subjects With Diabetic Macular Edema |
|
|
| Completed | 1 | 24 | RoW | IBI324 | Innovent Biologics (Suzhou) Co. Ltd. | Diabetic Macular Edema | 06/23 | 06/23 | | |
NCT05099094: VEGFA-targeting Gene Therapy to Treat Retinal and Choroidal Neovascularization Diseases |
|
|
| Recruiting | 1 | 18 | RoW | BD311 | Shanghai BDgene Co., Ltd., Eye & ENT Hospital of Fudan University | Neovascular Age-related Macular Degeneration, Diabetic Macular Edema, Retinal Vein Occlusion | 09/23 | 09/23 | | |
DME, NCT05802329: Phase I Study to Assess the Safety and Efficacy of OCU200 for Center-Involved Diabetic Macular Edema |
|
|
| Not yet recruiting | 1 | 28 | NA | OCU200 Low Dose, OCU200 study low dose up to 0.5 mg/mL., OCU200 Medium Dose, OCU200 study medium dose up to 1 mg/mL., OCU200 High Dose, OCU200 study high dose up to 2 mg/mL. | Ocugen | Center Involved Diabetic Macular Edema, Diabetic Macular Edema | 09/23 | 09/23 | | |
NCT05699759: Safety and Effect of Intravitreal Injection of a Derivative of Nucleoside Reverse Transcriptase Inhibitor in Subjects With Diabetic Macular Edema |
|
|
| Recruiting | 1 | 5 | US | K8, SOM-401 | Michelle Abou-Jaoude, Inflammasome Therapeutics | Diabetic Macular Edema | 12/24 | 12/24 | | |
NCT06205979: Relationship Between Dyslipidemia and The Response of Diabetic Macular Edema to Intravitreal Injection of Anti Vascular Endothelial Growth Factor Agents |
|
|
| Recruiting | 1 | 50 | RoW | Ranibizumab Injection [Lucentis], Aflibercept Injection [Eylea] | Sohag University | Diabetic Macular Edema | 06/24 | 06/24 | | |
NCT04187443: MS-553 in Diabetic Retinopathy Patients With Central Involved Macular Edema |
|
|
| Recruiting | 1 | 45 | RoW | MS-553 | Shenzhen MingSight Relin Pharmaceuticals Co., Ltd., Fountain Medical Development Co., Ltd. | Diabetic Macular Edema, Macular Edema, Type 2 Diabetes With Diabetic Macular Edema, Type 1 Diabetes With Diabetic Macular Edema, Diabetic Retinopathy | 12/23 | 01/24 | | |
NCT04690608: Suprachoroidal Injection of Triamcinolone Acetonide in Resistant Diabetic Macular Edema, CRVO, Pseudophakic Cystoid Macular Edema and Diabetic Macular Edema Following Pars Plana Vitrectomy |
|
|
| Not yet recruiting | 1 | 100 | RoW | Triamcinolone Acetonide 40Mg/Ml Inj,Susp_#1, 30 gauge syringe with 24 gauge cannula | Tanta University | Retinal Edema | 12/24 | 02/25 | | |
SKG0106-002, NCT06237777: A Clinical Study Evaluating the Safety, Tolerability and Initial Efficacy of SKG0106 Intravitreal Injection in Diabetic Macular Edema (DME) Patients |
|
|
| Recruiting | 1 | 18 | RoW | SKG0106 intravitreal injection dose level 1, 2 or 3, SKG0106 | Wang Min, Lanyue Biotech (Hangzhou) Co., Ltd. | Diabetic Macular Edema | 01/26 | 01/26 | | |
NCT05940428: A Study of ASKG712 in Patients With Diabetic Macular Edema |
|
|
| Not yet recruiting | 1 | 26 | RoW | ASKG712, AM712 | AskGene Pharma, Inc., Suzhou Aosaikang Biopharmaceutical Co., Ltd. | Diabetic Macular Edema | 12/24 | 07/25 | | |
NCT05698329: Effect of AIV007 by Periocular Administration in Subjects With nAMD or DME |
|
|
| Recruiting | 1 | 30 | US | AIV007 | AiViva BioPharma, Inc. | Neovascular Age-related Macular Degeneration, Diabetic Macular Edema | 02/25 | 04/25 | | |
| Recruiting | 1 | 18 | RoW | FT-003 | Frontera Therapeutics, Tianjin Medical University Eye Hospital, Peking Union Medical College Hospital, The First Affiliated Hospital of Zhengzhou University | Diabetic Macular Edema | 05/25 | 05/28 | | |
